Epigenetic regulation of the neuroendocrine axis in brain development and behavior

Active Grant Awarded Last action

Award ID
R01MH133600
Recipient
Awarding agency
Obligated
$1,272,058

Award facts

Assistance listing
93.24R Mental Health Research - Research Projects
Completion date 41% complete
Place of performance
Omaha, NE 68178, USA

Award details come from USAspending.gov.

Description

Abstract
Lysine methyltransferase 5B (KMT5B) is part of a gene family that modulates the methylation state of histone 4 lysine 20 (H4K20) residues, and H4K20 methylation regulates gene expression by altering chromatin compaction. Heterozygous disruptive variants in KMT5B have been associated with human neurodevelopmental disease-specifically, KMT5B has been identified as one of the most mutated genes in autism spectrum disorder (ASD), a highly prevalent and lifelong condition. Phenotypes reported among KMT5B patients and in our KMT5B mouse model suggest that KMT5B may have a role in the epigenetic expression of the insulin-like growth factor (IGF) family, which includes two members-IGF1 and IGF2. These hormones can be expressed in an endocrine (CIRCULATING) or paracrine (LOCAL) fashion and have been strongly linked to autism. We hypothesize that KMT5B regulates the expression of thegenes driving the primary neurodevelopmental phenotypes observed. We will test our central hypothesis and, thereby, accomplish the overall objective of this project through three specific aims. First, we will specify the role that KMT5B plays in paracrineproduction (i.e., LOCAL brain expression) using both constitutive and brain-specific knockout models. Second, we will define how endocrineexpression (i.e., CIRCULATING and expressed postnatally by the liver) changes relative to KMT5B expression over time and how this impacts (1) brainexpression and (2) KMT5B-linked behavioral phenotypes. We will compare the results of these two aims to identify whether IGF1 and IGF2 are differentially or similarly regulated by KMT5B and whether rescue can be achieved by targeting either system. Finally, we will use a combination of atac SEQ and RNA SEQ to identify cell types where KMT5B regulates the expression of igfs and whether these effects can be therapeutically rescued. Our results will increase our understanding of how KMT5B interacts with theaxis, how igfs are epigenetically regulated, and how IGF1 and IGF2 are regulated in different tissues over time. We expect the outcomes of this study to define the contribution of KMT5B to autism clinical features while illuminating novel drug targets for the treatment of this clinical population.

Transactions

Action Obligated Date
Amendment $397,747
Amendment $434,507
Original award $439,804

Quick answers

Who received award R01MH133600?

R01MH133600 was awarded to Creighton University by National Institute of Mental Health (National Institutes of Health) on November 13, 2024.

How much is award R01MH133600 worth?

$1,272,058 has been obligated on R01MH133600.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award